{"id":39505,"date":"2026-08-03T10:10:36","date_gmt":"2026-08-03T08:10:36","guid":{"rendered":"https:\/\/ggba.swiss\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/"},"modified":"2026-08-03T10:12:29","modified_gmt":"2026-08-03T08:12:29","slug":"immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/","title":{"rendered":"Immitra Bio l\u00e8ve CHF 2,4 millions pour d\u00e9velopper sa plateforme d&rsquo;\u00e9dition g\u00e9nique in vivo"},"content":{"rendered":"\n<p><a href=\"https:\/\/immitrabio.com\/\">Immitra Bio<\/a> a boucl\u00e9 un tour de financement de pr\u00e9-amor\u00e7age sursouscrit de CHF 2,4 millions. CHF 2,25 millions proviennent d&rsquo;investisseurs en capital-risque et priv\u00e9s, auxquels s&rsquo;ajoutent CHF 150&rsquo;000 obtenus par des financements non dilutifs. Le tour a \u00e9t\u00e9 men\u00e9 par Backbone Ventures et co-men\u00e9 par OCCIDENT, avec la participation d&rsquo;Another VC, Kickfund, Venture Kick, la Z\u00fcrcher Kantonalbank, la <a href=\"https:\/\/www.fongit.ch\/\">FONGIT<\/a>, la Fondation ETH et des investisseurs priv\u00e9s.<\/p>\n\n\n\n<p>L&rsquo;entreprise d\u00e9veloppe une plateforme de th\u00e9rapies d&rsquo;\u00e9dition g\u00e9nique in vivo curatives en une seule administration, combinant une technologie d&rsquo;\u00e9dition g\u00e9nique ind\u00e9pendante de la mutation et une plateforme num\u00e9rique d&rsquo;identification de cibles. Cette approche vise \u00e0 \u00e9viter la manipulation cellulaire ex vivo complexe, le conditionnement du patient et la greffe de cellules souches qu&rsquo;exigent les th\u00e9rapies actuelles, et \u00e0 produire des formulations pr\u00eates \u00e0 l&#8217;emploi capables de traiter tous les patients atteints d&rsquo;une maladie donn\u00e9e, quelle que soit la mutation en cause.<\/p>\n\n\n\n<p>Les fonds soutiendront principalement les \u00e9tudes pr\u00e9cliniques de preuve de concept pour IB-003, le candidat principal de l&rsquo;entreprise et traitement potentiellement curatif en une seule administration contre une an\u00e9mie h\u00e9r\u00e9ditaire. Le financement appuiera \u00e9galement les travaux de d\u00e9couverte et de validation sur l&rsquo;ensemble du pipeline, rendus possibles par sa plateforme num\u00e9rique de d\u00e9couverte de cibles, ainsi que la poursuite de l&rsquo;am\u00e9lioration de la plateforme.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immitra Bio a boucl\u00e9 un tour de pr\u00e9-amor\u00e7age sursouscrit de CHF 2,4 millions pour d\u00e9velopper sa plateforme d&rsquo;\u00e9dition g\u00e9nique in vivo \u00e0 grande \u00e9chelle et son candidat principal contre une an\u00e9mie h\u00e9r\u00e9ditaire.<\/p>\n","protected":false},"author":6,"featured_media":39502,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1245,1142],"class_list":["post-39505","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-gene-therapy-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immitra Bio l\u00e8ve CHF 2,4 millions pour l&#039;\u00e9dition g\u00e9nique in vivo<\/title>\n<meta name=\"description\" content=\"Immitra Bio boucle un tour de pr\u00e9-amor\u00e7age de CHF 2,4 millions pour d\u00e9velopper sa plateforme d&#039;\u00e9dition g\u00e9nique in vivo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immitra Bio l\u00e8ve CHF 2,4 millions pour l&#039;\u00e9dition g\u00e9nique in vivo\" \/>\n<meta property=\"og:description\" content=\"Immitra Bio boucle un tour de pr\u00e9-amor\u00e7age de CHF 2,4 millions pour d\u00e9velopper sa plateforme d&#039;\u00e9dition g\u00e9nique in vivo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T08:10:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-03T08:12:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Immitra Bio l\u00e8ve CHF 2,4 millions pour d\u00e9velopper sa plateforme d&rsquo;\u00e9dition g\u00e9nique in vivo\",\"datePublished\":\"2026-08-03T08:10:36+00:00\",\"dateModified\":\"2026-08-03T08:12:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/\"},\"wordCount\":257,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Gene Therapy\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/\",\"name\":\"Immitra Bio l\u00e8ve CHF 2,4 millions pour l'\u00e9dition g\u00e9nique in vivo\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg\",\"datePublished\":\"2026-08-03T08:10:36+00:00\",\"dateModified\":\"2026-08-03T08:12:29+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Immitra Bio boucle un tour de pr\u00e9-amor\u00e7age de CHF 2,4 millions pour d\u00e9velopper sa plateforme d'\u00e9dition g\u00e9nique in vivo.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"L\u2019\u00e9quipe d\u2019Immitra Bio d\u00e9veloppe des th\u00e9rapies d'\u00e9dition g\u00e9nique in vivo con\u00e7ues comme des traitements pr\u00eats \u00e0 l'emploi, efficaces quelle que soit la mutation sous-jacente du patient. | \u00a9 Immitra Bio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immitra Bio l\u00e8ve CHF 2,4 millions pour d\u00e9velopper sa plateforme d&#8217;\u00e9dition g\u00e9nique in vivo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immitra Bio l\u00e8ve CHF 2,4 millions pour l'\u00e9dition g\u00e9nique in vivo","description":"Immitra Bio boucle un tour de pr\u00e9-amor\u00e7age de CHF 2,4 millions pour d\u00e9velopper sa plateforme d'\u00e9dition g\u00e9nique in vivo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/","og_locale":"fr_FR","og_type":"article","og_title":"Immitra Bio l\u00e8ve CHF 2,4 millions pour l'\u00e9dition g\u00e9nique in vivo","og_description":"Immitra Bio boucle un tour de pr\u00e9-amor\u00e7age de CHF 2,4 millions pour d\u00e9velopper sa plateforme d'\u00e9dition g\u00e9nique in vivo.","og_url":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-08-03T08:10:36+00:00","article_modified_time":"2026-08-03T08:12:29+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Immitra Bio l\u00e8ve CHF 2,4 millions pour d\u00e9velopper sa plateforme d&rsquo;\u00e9dition g\u00e9nique in vivo","datePublished":"2026-08-03T08:10:36+00:00","dateModified":"2026-08-03T08:12:29+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/"},"wordCount":257,"image":{"@id":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg","keywords":["Biotech","Financing","Gene Therapy","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/","url":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/","name":"Immitra Bio l\u00e8ve CHF 2,4 millions pour l'\u00e9dition g\u00e9nique in vivo","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg","datePublished":"2026-08-03T08:10:36+00:00","dateModified":"2026-08-03T08:12:29+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Immitra Bio boucle un tour de pr\u00e9-amor\u00e7age de CHF 2,4 millions pour d\u00e9velopper sa plateforme d'\u00e9dition g\u00e9nique in vivo.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg","width":1180,"height":811,"caption":"L\u2019\u00e9quipe d\u2019Immitra Bio d\u00e9veloppe des th\u00e9rapies d'\u00e9dition g\u00e9nique in vivo con\u00e7ues comme des traitements pr\u00eats \u00e0 l'emploi, efficaces quelle que soit la mutation sous-jacente du patient. | \u00a9 Immitra Bio"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/immitra-bio-leve-chf-24-millions-pour-developper-sa-plateforme-dedition-genique-in-vivo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Immitra Bio l\u00e8ve CHF 2,4 millions pour d\u00e9velopper sa plateforme d&#8217;\u00e9dition g\u00e9nique in vivo"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=39505"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39505\/revisions"}],"predecessor-version":[{"id":39507,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39505\/revisions\/39507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/39502"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=39505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=39505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=39505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}